Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and S-1 in recurrent or metastatic head and neck malignancies
NCT03654612Phase 2Unknown
- Sponsor
- China International Medical Foundation
- Start
- Oct 2018
- Primary completion
- Mar 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in head and neck cancer (HNC), sponsored by China International Medical Foundation. Primary endpoint: Progression-Free Survival at 40 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT03654612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654612.